60%+ returns in 2025: Here’s how AI-powered stock investing has changed the game
Investing.com -- Plus Therapeutics Inc (NASDAQ:PSTV) stock gained 8.4% in premarket trading Thursday after the company announced its subsidiary CNSide Diagnostics signed a national agreement with Humana Inc (NYSE:HUM).
The agreement, effective October 29, 2025, will provide coverage for CNSide’s Cerebrospinal Fluid Tumor Cell Enumeration laboratory developed test to approximately 16 million people throughout the United States. This brings the total policy coverage for the test to 67 million people.
The CNSide CSF Assay Platform is designed to support rapid diagnoses, treatment monitoring, and treatment guidance for patients with leptomeningeal metastases. According to the company, the test has demonstrated superior clinical utility over standard of care in nine peer-reviewed publications and the FORESEE clinical trial.
Since 2020, more than 11,000 CNSide tests have been performed at over 120 U.S. cancer institutions. The company reports the test delivers high sensitivity (92%) and specificity (95%), while influencing treatment decisions in 90% of cases.
The test is available exclusively through CNSide Diagnostics as a testing service provided to healthcare professionals in the United States.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.